The Rosen Law Firm, P.A. announces that it is investigating potential
securities fraud claims against Regado Biosciences, Inc. (NASDAQ:RGDO)
resulting from allegations that the Company may have made false and
misleading disclosures concerning its Phase 3 clinical trials.
On July 2, 2014 Regado Biosciences announced the suspension of its Phase
3 study of its anticoagulant drug, REG1 (now known as Revolixys Kit),
pending a review of potential safety problems. In its announcement,
Regado Biosciences stated: "that the Data Safety Monitoring Board, or
DSMB, has initiated an unplanned review of data from the Company's Phase
3 trial of Revolixys Kit (previously known as REG1), entitled
REGULATE-PCI, and that patient enrollment has been paused in the
REGULATE-PCI tria until the DSMB has completed its analysis and
communicated its recommendations." Regado Biosciences further explained
that: "[t]he DSMB will conduct a full analysis of safety and treatment
benefit-risk ratio of all patients enrolled to date (3234) with a focus
on serious adverse events related to allergic reactions." Upon this
news, shares of Regado Biosciences fell dramatically, damaging investors.
The Rosen Law Firm is preparing a class action lawsuit on behalf of
Regado Biosciences investors. If you purchased Regado Biosciences
securities prior to July 3, 2014, you may visit the website at http://rosenlegal.com
to join the action. You may also contact Phillip Kim, Esq. or Kevin
Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail
at email@example.com or firstname.lastname@example.org.
The Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and shareholder
Attorney Advertising. Prior results do not guarantee a similar outcome.
[ Back To NFVZone's Homepage ]